Inoue H, Ishihara T, Kobayashi K, Fukai S
J Thorac Cardiovasc Surg. 1978 Oct;76(4):479-82.
Delayed hypersensitivity reactions before therapy in 137 patients with lung cancer and in 50 patients with benign thoracic lesions were evaluated by 2,4-dinitrochlorobenzene (DNCB) contact sensitization using the patch test. Ninety-eight percent (49/50) of control patients and 46 percent (62/137) of patients with lung cancer were sensitized by 250 mug of DNCB. There was an excellent correlation between the initial reactivity to DNCB and resectability. In patients with resectable lung cancer, preoperative DNCB reactivity has no prognostic value. However, an excellent correlation was found between postoperative reactivity and 2 year survival, i.e., conversion from unresponsive to responsive status was observed on sequential testing. In 15 of 74 patients with resectable disease, the conversion was noted postoperatively, and among 12 patients followed for 2 years, only two patients had died. Conversion from a reactive to nonreactive status to DNCB occurred only in the terminal stage of the disease. From these observations, we found that, in order to evaluate the afferent limb of cellular immunity in patients with lung cancer who have once expressed reactivity to DNCB, one must use some new sensitizing agents which show no cross-sensitivity with each other thereafter.
采用斑贴试验，通过2,4 -二硝基氯苯（DNCB）接触致敏法对137例肺癌患者和50例良性胸部病变患者治疗前的迟发型超敏反应进行了评估。250微克DNCB使98%（49/50）的对照患者和46%（62/137）的肺癌患者致敏。DNCB初始反应性与可切除性之间存在良好的相关性。在可切除肺癌患者中，术前DNCB反应性无预后价值。然而，术后反应性与2年生存率之间存在良好的相关性，即连续检测时观察到从不反应状态转变为反应状态。在74例可切除疾病患者中的15例中，术后出现了这种转变，在随访2年的12例患者中，仅2例死亡。从反应状态转变为对DNCB无反应状态仅发生在疾病的终末期。从这些观察结果中，我们发现，为了评估曾经对DNCB有反应的肺癌患者的细胞免疫传入支，必须使用此后彼此无交叉敏感性的一些新致敏剂。
